This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A nephropathy (IgAN), a chronic kidney disease. The Japanese biopharma is now looking ahead to a prospective phase 3 trial of mezagitamab. The data was presented at the European Renal Association Congress on 6 June 2025 […] The post Takeda presents positive results from trial of chronic kidney disease treatment appeared first on Pharmafi
When it comes to weight loss drugs, GLP-1 (glucagon-like peptide-1 receptor agonist) medications like Wegovy and Ozempic are all the rage—and they’re highly effective. While both medications have the same active ingredient, semaglutide, they have different FDA-approved uses. Ozempic is approved to manage Type 2 diabetes. Wegovy is approved for weight loss in adults with obesity (a body mass index of 30 or greater) or overweight individuals (BMI of 27 or more) with at least one weight-relat
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Practical strategies for pharmacy professionals to build a social media presence, expand their network, and advance their careers in the evolving digital landscape.
We recently went viral. Well, not exactly us — but people like us. We are participants in the Yale LISTEN Study , a patient-centered study to better understand long Covid and the adverse effects some patients have experienced post Covid-vaccination. We are members of the post-vaccination cohort, a group that includes more than 250 patients.
We recently went viral. Well, not exactly us — but people like us. We are participants in the Yale LISTEN Study , a patient-centered study to better understand long Covid and the adverse effects some patients have experienced post Covid-vaccination. We are members of the post-vaccination cohort, a group that includes more than 250 patients.
By translating clinical evidence and real-world data into meaningful care, pharmacists uniquely position themselves to guide patients on GLP-1 therapies in obesity.
June 10, 2025 – Lubrizol announces that an Apisolex™ polymer excipient-enabled drugformulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-basedpolymer that enhances the solubility of BCS Class II and IV active pharmaceuticalingredients (API). Apisolex polymer excipient is manufactured following GoodManufacturing Practices (GMP) guidelines and […] The post Lubrizol announces an important milestone for its novelpatent
Low uptake of vaccination to protect against invasive pneumococcal disease (IPD) was observed both before and after a pneumococcal-related hospitalization, with countless missed vaccination opportunities documented.
Medical groups, public health leaders and lawmakers were quick to condemn Monday's announcement that all 17 sitting members of the Advisory Committee on Immunization Practices are being removed.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Panelists discuss how anticipated updates to cholesterol guidelines and related cardiovascular-kidney-metabolic health (CKM) guidelines this year are expected to shape low-density lipoprotein cholesterol (LDL-C) management strategies and influence treatment recommendations for high-risk patients.
Discover how statistical methodologies are transforming drug development by leveraging real-world evidence (RWE) to improve decision-making and outcomes. Explore the impact and benefits of utilising RWE in pharmaceutical research.
In the third part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, comments on how mobile and digital solutions can be deployed effectively to close the gap in areas identified as pharmacy deserts.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
In 2019, a National Health Interview Survey found that back pain was the most common location for pain, with 39% of adults saying they’d experienced it in the last three months. As a common healthcare concern that can interfere with normal activities, there are several treatment options available. Occasionally, doctors will prescribe prednisone to treat back pain, but this is usually in specific situations.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Weight loss is a huge industry in the United States. Americans spend an estimated $33 billion every year in pursuit of shedding pounds, according to the National Institutes of Health. And a sizable chunk of that spending is on weight loss drugs. Contrave (naltrexone/bupropion) is a popular choice, and by increasing dopamine in the brain, it can help reduce appetite and body weight.
Nurses flagged staffing, clinician biases, technologies addressing language barriers and more as key factors affecting hospital care for socially disadvantaged patients.
ANGLE has announced three new peer-reviewed publications demonstrating the use of its Parsortix circulating tumour cell (CTC) harvesting system in studies exploring cancer biology and therapeutic targets. The research, led by academic groups in Germany, Ireland and the US, supports the system’s growing role in advancing oncology R&D. In one study, published in Journal of […] The post ANGLE’s Parsortix system used in new cancer biology research appeared first on Pharmafile.
A systematic review determines if adult patients with language barriers are less likely to use the video-based virtual care option, while exploring equity and accessibility gaps when it comes to telehealth.
Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking approved drugs to market.
WuXi Biologics has announced that construction of its new 95,000m 2 microbial manufacturing site in the Wenjiang district of Chengdu, China, has begun. With both a drug substance and a drug product facilities, the site will enable commercial production for multiple modalities, including peptides, antibody fragments, plasmid DNA and virus-like particles (VLPs).
Biotechnology has become a pillar of national resilience. Once considered niche, fields like synthetic biology, pathogen genomics, computational biology, and environmental microbiology now sit at the heart of U.S. biosecurity strategy, economic competitiveness, and geopolitical influence. Yet the nation’s training infrastructure remains dangerously underdeveloped.
News All News Bio/Pharma News Publications All Publications PharmTech PharmTech Europe Resources Marketplace ICH Q9 Revision: A Comprehensive Resource on Quality Risk Management Peer-Reviewed Research PharmTech Products Pharma Insights Sponsored Podcasts Sponsored Videos Sponsored eBooks Whitepapers Webcasts Multimedia All Videos Ask the Expert Behind The Headlines Buy, Sell, Hold Drug Digest Videos Drug Solutions Podcast Peer Exchange Sexy Science Tech Talk Conference Conference Coverage Confer
Somnee, a neuroscience-based sleep tech company, picked up $10 million in a seed extension round as the company preps to launch the second generation of its sleep tech wearable device.
Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Jobs Tagomics secures £860k grant for colorectal cancer test by John Pinching | 10th Jun 2025 | News Biotech firm to collaborate with NHS on early detection study Tagomics has been awarded £860k in funding from Innovate UK’s Biomedical Catalyst programme to develop a novel diagnostic test for colorectal cance
Hansa Biopharma (Hansa) will host a virtual investor event on Guillain-Barré syndrome (GBS) on 16 June 2025. The webcast aims to highlight the company’s ongoing research efforts and pipeline developments targeting this rare neurological condition. The event will feature expert insights into the GBS treatment landscape. David Cornblath, professor emeritus of neurology at Johns Hopkins […] The post Hansa Biopharma to host investor event on Guillain-Barré Syndrome to accelerate research appea
52
52
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
247 
Let's personalize your content